Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03011684 · ClinicalTrials.gov registry record · Phase 3
Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial
A Phase 3 study of Infertility, sponsored by University of California, San Francisco.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 309
- Enrollment target
- 1
- Study location
NCT03011684 is a Phase 3 study of Infertility that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 309 participants, below the 7,585-participant average among 74 other Infertility trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03011684, a Phase 3 study of Infertility, is actively recruiting participants, sponsored by University of California, San Francisco.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 309 participants
- Enrollment target
- 1
- Study location
Study Summary
Latrogenic infertility as a result of cancer treatment has a profound effect on long-term quality of life in survivors of reproductive-age cancers. Oocyte cryopreservation prior to cancer treatment has been associated with improved quality of life, with a potential ability to reduce long-term decision-related regret in cancer survivors. Though letrozole plus gonadotropin and and tamoxifen plus gonadotropin are currently routinely used worldwide in ovarian stimulation cycles for fertility preservation in patients with estrogen-receptor-positive breast cancer, it is not clear which of the two might lead to improved oocyte yield. Improved knowledge about the efficacy of these medications, with regard to oocyte yield, has the potential to significantly improve quality of life in reproductive-age breast cancer survivors.
Conditions Studied
Interventions
- DRUG Tamoxifen
- DRUG Letrozole
Study Locations (1)
California
- University of California at San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 309 participants |
| Start Date | 2016-07-21 |
| Est. Completion | 2026-03-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03011684
The ClinicalTrials.gov registry entry for NCT03011684 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 309 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 7,585-participant average among 74 other Infertility trials with a reported enrollment target (96% lower). The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Infertility appearing as the primary indexed condition, and to 2 interventions - of which Tamoxifen is the first listed.
NCT03011684 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT03011684 about?
NCT03011684 is a clinical study titled "Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial". Latrogenic infertility as a result of cancer treatment has a profound effect on long-term quality of life in survivors of reproductive-age cancers. Oocyte cryopreservation prior to cancer treatment has been associated with improved quality of life, with a potential ability to reduce long-term decisi...
What is the current status of trial NCT03011684?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 309 participants. The study started on 2016-07-21. Estimated completion is 2026-03-31.
What conditions does trial NCT03011684 study?
This clinical trial studies the following conditions: Infertility.
What interventions are being tested in trial NCT03011684?
The interventions under investigation include: Tamoxifen (DRUG), Letrozole (DRUG).
Who is sponsoring clinical trial NCT03011684?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03011684 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Infertility
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pre-IVF Treatment With a GnRH Antagonist in Women With endometriosis_temp
RECRUITING · Phase 3
-
Subcutaneous Progesterone in Frozen- Thawed Single Euploid Blastocyst Transfer.
ACTIVE NOT RECRUITING · Phase 3
-
Vaginal Culture Using INVOcell Compared to Traditional IVF Incubation
COMPLETED · Phase 3
-
Comparison of MENOPUR Liquid and Powder in Women Undergoing Assisted Reproductive Technology (ART)
COMPLETED · Phase 3
-
A Clinical Trial to Evaluate the Efficacy and Safety of DR-2011 for In Vitro Fertilization
COMPLETED · Phase 3
-
Gamete Treatment to Correct Fertilization Failure
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.